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Tau oligomers impair memory and induce
synaptic and mitochondrial dysfunction in
wild-type mice




Background: The correlation between neurofibrillary tangles of tau and disease progression in the brains of
Alzheimer’s disease (AD) patients remains an area of contention. Innovative data are emerging from biochemical,
cell-based and transgenic mouse studies that suggest that tau oligomers, a pre-filament form of tau, may be the
most toxic and pathologically significant tau aggregate.
Results: Here we report that oligomers of recombinant full-length human tau protein are neurotoxic in vivo after
subcortical stereotaxic injection into mice. Tau oligomers impaired memory consolidation, whereas tau fibrils and
monomers did not. Additionally, tau oligomers induced synaptic dysfunction by reducing the levels of synaptic
vesicle-associated proteins synaptophysin and septin-11. Tau oligomers produced mitochondrial dysfunction by
decreasing the levels of NADH-ubiquinone oxidoreductase (electron transport chain complex I), and activated
caspase-9, which is related to the apoptotic mitochondrial pathway.
Conclusions: This study identifies tau oligomers as an acutely toxic tau species in vivo, and suggests that tau
oligomers induce neurodegeneration by affecting mitochondrial and synaptic function, both of which are early
hallmarks in AD and other tauopathies. These results open new avenues for neuroprotective intervention strategies
of tauopathies by targeting tau oligomers.
Introduction
The major biological functions of the microtubule-asso-
ciated protein tau, include: microtubule assembly, axonal
transport, neurite outgrowth, and stability of microtu-
bules [1]. Most of the biological functions of tau are
modulated by site-specific phosphorylation [2]. Tau self-
assembly, aggregation, and accumulation in neurofibril-
lary tangles (NFTs) are hallmarks of Alzheimer’s disease
(AD) and other neurodegenerative diseases [3,4].
Although the importance of tau in AD and other tauo-
pathies is well-established [5-7], unanswered is whether
NFTs are the primary neurotoxic factor. Most research
has focused on NFTs because of the reported correla-
tion between NFTs and disease progression in the brains
of AD patients [8-10]. However, recent data suggest that
soluble pre-filament forms of tau may be the most toxic
and pathologically significant forms of tau aggregates
[11,12]. Cell death and synaptic lesions occur indepen-
dently of formation of NFTs in h-tau mice expressing
non-mutant human tau [13,14]. Hippocampal synapse
loss and microgliosis precede formation of NFTs in the
P301S transgenic mouse model (P301S Tg) [15]. More-
over, tau oligomers were biochemically characterized in
a conditional model (rTg4510) expressing the P301L h-
tau mutant. Surprisingly, the best correlate of neuronal
loss and behavioral deficits in these models was the
accumulation of oligomeric tau, whereas there was no
relation with NFTs [16,17]. In addition, stereologic stu-
dies of human AD show that neuronal loss actually pre-
cedes NFT formation [18,19]. Granular tau oligomers
were detected and biochemically isolated at very early
stages of the disease, when clinical symptoms of AD and
NFTs are believed to be absent [20,21], and tau-positive
fine granules were found in postmortem tissue from the
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pathy [22]. Even more recently, tau oligomers were
detected in platelets from AD patients, suggesting that
this species of tau protein could serve as a new biologi-
cal marker for AD [23].
Mechanistic studies of aggregation of full-length tau
protein in vitro revealed that tau aggregates by means of
either a nucleation-dependent mechanism [24] or by the
formation of intermediates [25]. In the present study,
we investigated the neurotoxicity of different forms of
tau in vivo by injecting well-characterized oligomers,
fibrils, or monomers of full-length recombinant h-tau-
441 (2N4R) into the hippocampus of C57BL/6 wild-
mice. We found that the mice injected with tau oligo-
mers presented with memory deficits in their novel-
object recognition task, which is widely used for evaluat-
ing memory in AD mouse models [26-29].
We also determined the loss of synaptic-related pro-
teins and mitochondrial respiratory chain components
in conjunction with the activation of the mitochondrial
dysfunction markers and the pro-apoptotic protein cas-
pase-9. Our results strongly suggest that accumulation
of tau oligomers result in learning impairment through
the disruption of synaptic and mitochondrial functions.
Methods
Preparation of tau oligomers and fibrils
Recombinant tau protein (tau-441 (2N4R) M.Wt 45.9
kDa) was expressed and purified as described [30,83]. In
brief, we transformed the BL21 (DE3) strain of Escheri-
chia coli with pET-28 plasmids and grown in LB med-
ium at 37°C under vigorous shaking. At an OD600 of
0.4-0.6, we induced protein expression with 1 mM iso-
propyl b-D-thiogalactoside. Bacteria were incubated for
an additional 3 h and then centrifuged for 20 min at
3,500 × g. Pellets were resuspended in 500 mM NaCl,
20 mM PIPES (pH 6.5), 1 mM EDTA, and 50 mM 2-
mercaptoethanol. After 10 min on ice, we sonicated the
samples 3 × 30 sec at power setting seven. We pelleted
the bacterial debris for 20 min at 10,000 × g and soluble
tau protein was precipitated from supernatant by using
ammonium sulfate (60%, m/V). After 1 h on ice, sam-
ples were centrifuged for 10 min at 10,000 × g.P e l l e t s
were resuspended in purified H2O, 2 mM dithiothreitol
(DTT), and loaded onto cation exchange column (Bio-
Rad). Protein was eluted from the column in a 0.05-1 M
NaCl gradient containing 20 mM PIPES (pH 6.5), 0.5
mM EDTA, and 2 mM DTT. We analyzed the fractions
using SDS-PAGE; and we pooled tau protein samples
and added 5 mM DTT. The protein was purified using
Superdex column (Amersham Pharmacia). Elution
occurred with 100 mM NaCl, 10 mM PIPES (pH 6.5), 1
mM EDTA, and 2 mM DTT. Pooled samples of mono-
meric tau and added to 5 mM DTT. At that point, the
protein was >95% pure, as assessed by SDS-PAGE. For
storage, tau was precipitated overnight on ice with an
equal volume of MetOH, centrifuged for 20 min at
10,000 × g, washed once with MetOH and 2 mM DTT,
and stored at -80°C. Protein concentrations were deter-
mined at 276 nm in 6 M guanidinium chloride. We
treated the recombinant tau with 8 M urea to obtain
monomeric tau, then dialyzed overnight against 1 ×
phosphate-buffered saline (PBS), pH 7.4, normalized to
1 mg/mL with PBS and aliquots of tau monomer in PBS
were kept at -20°C.
Tau oligomers were prepared as previously described
[36]. Specifically, 300 μL of the tau stock (1 mg/mL) was
added to 700 μL of PBS 1 ×, final concentration (0.3 mg/
mL). Seven microliters of b42 amyloid (Ab42) oligomers
(0.3 mg/mL) was added as seeds and the sample was
mixed by pipetting for 1 min. We incubated the sample
at room temperature for 1 h on an orbital shaker. We
purified the resulting tau oligomers by fast protein liquid
chromatography (FPLC) and used them to seed a fresh
sample of monomeric tau; after two rounds of seeding
monomeric tau with purified tau oligomers, all Ab oligo-
mer seeds are eliminated. The samples have no Ab as
tested by either enzyme-linked immunosorbent assay
(ELISA) or Western blotting using 4G8. This is not sur-
prising since we used (1:140) Ab/tau ratio in the first
round, which is less than the standard used in the litera-
ture as seeds to promote aggregation. After three rounds,
there was less than 1:2,470,000 Ab/tau, which is below
the detection limits of the methods available. To prepare
the fibrils, tau oligomers were allowed to mix 1-2 days on
the orbital shaker. Tau preparations were characterized
by atomic force microscopy (AFM) by a non-contact tap-
ping method (ScanAsyst-air) using a Multimode 8 AFM
machine (Veeco, CA), and purified by size-exclusion
chromatography, using an LC-6AD Shimadsu high-per-
formance liquid chromatography (HPLC) system fitted
with a TSK-GEL G3000 SWXL (30 cm × 7.8 mm) col-
umn, Supelco-808541. PBS, pH 7.4, was used as the
mobile phase, flow rate 0.5 mL/min. Gel filtration stan-
dard (Bio-Rad 51-1901) was used for calibrations.
Animals
Thirty-six male C57BL/6 mice (body weight: 30 ± 2 g)
were used at the age of 20 weeks. The mice had free
access to food and water and were maintained on a 12-
h dark-light cycle in a controlled temperature room (25°
C ± 2°C) for the duration of the study. The animals
were divided into three groups of twelve mice. In one
group, mice were injected with tau oligomers and PBS;
i nas e c o n dg r o u p ,m i c ew e r ei n j e c t e dw i t ht a uf i b r i l s
and PBS; in the third group, mice were injected with tau
monomers and PBS. All animal experiments were per-
formed in accordance with IACUC approved protocols.
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We anesthetized male C57BL/6 mice with ketamine (10
mg/mL) and xylazine (1.5 mg/mL), and then positioned
on a stereotaxic frame. Once we identified bregma and
drilled holes in that location, 1 μL of 0.9 mg/mL of var-
ious tau preparations and/or the same volume of PBS
buffer were injected into the hippocampus in the left
and right hemispheres, respectively (-2.06 mm posterior,
+/-1.75 mm lateral, and 2.5 mm ventral to the bregma)
at a rate of 0.2 μL/min.
Object recognition task
Mice were tested in an open-square white arena, 60 ×
60 cm, 40 cm high. The following objects were used: a
black metal cylinder, 6 × 7 cm; an orange disk, 1.5 × 5
cm; and a plastic cube, 4 × 4 cm. The task started with
a habituation trial, during which the animals were
placed in the empty arena for 10 min. The next day,
mice were injected with the corresponding tau species
and/or the vehicle (PBS). Twenty-four hours later, the
mice were again placed in the same arena containing
two identical objects (familiarization phase). Exploration
was recorded in a 10-min trial. Sniffing, touching, and
stretching the head toward the object at a distance of
no more than 2 cm were scored as object investigation
[29]. Six hours later (test phase), mice were again placed
in the arena containing two objects: one identical to one
of the objects presented during the familiarization phase
(familiar object), and a new, different object (novel
object). The time spent exploring the two objects was
recorded for 10 min. Memory was expressed as a discri-
mination index, namely (seconds on novel-seconds on
familiar)/(seconds on novel + seconds on familiar) and
was expressed as the percentage of time on each object.
Animals with no memory impairment spend a longer
time investigating the novel object compared with the
familiar object, giving a higher discrimination index. At
the end of the experiment, we euthanized the mice using
cervical dislocation and dissected the brains of six ani-
mals per group. We then fixed these brains in 4% buf-
fered paraformaldehyde, and embedded them in paraffin
for histological analysis. The brains from the other six
mice of each group were frozen for biochemical analysis.
Western blot analysis
We divided each brain into hemispheres and then the
hippocampus was isolated and homogenized in ice-cold
PBS with protease inhibitors (5% w/v). We centrifuged
the homogenates for 10 min at 300 g. Next, we quantified
the proteins in the supernatant using a Bradford assay
(Sigma, B6916) and separated equal amounts of them
using an SDS-PAGE and then we transferred them onto
nitrocellulose. After being blocked with non-fat dried
milk, membranes were probed with anti-synaptophysin
(1:1000, Abcam, ab8049), anti-complex V d-subunit
(1:2000, Invitrogen, 459000), anti-complex I subunit
(1:1000, Invitrogen 459210), anti-caspase-9 (1:4000,
Abcam, ab8087), anti-tubulin (1:1500, Oncogene, CP06),
anti-synapsin-1 (1:3000, Abcam, ab8), anti-septin 11
(1:2000, Abcam, ab86268), anti-active caspase-3 (1:1000,
Abcam, ab2302), and anti-caspase-8 antibody (1:4000,
Abcam, ab52183). The first five antibodies immunoreactiv-
ity was detected with horseradish peroxidase (HRP)-conju-
gated anti-mouse IgG (1:3000, Jackson ImmunoResearch
Laboratories, Inc. West Grove, PA) and anti-rabbit IgG
(1:3000, Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) for other the four antibodies, followed by elec-
trochemiluminescence (Thermo Scientific, Rockford, IL).
Immunohistochemical and microscopic analysis
Paraffin sections were deparaffinized, rehydrated, and
washed in 0.01 mol/L PBS for 5 min., repeated three
times. After blocking in normal goat serum for 1 h, sec-
tions were incubated overnight with mouse monoclonal
anti-synaptophysin antibody (predilute; Chemicon,
IHCR1011-6) or mouse monoclonal (2-23) antibody to
caspase-9 (1:200; Abcam, ab78087) or mouse monoclo-
nal anti-NeuN antibody (1:1000, Chemicon, MAB377).
T h en e x td a yt h es e c t i o n sw e r ew a s h e di nP B St h r e e
times for 10 min and then incubated with goat anti-
mouse IgG alexa488 (1:700; Invitrogen, A11004) for 1 h.
Later, we washed the sections three times for 10 min in
PBS, and finally we applied VECTASHIELD mounting
medium with DAPI staining (Vector Lab., H-1000) and
the slide was coverslipped and sealed with clear nail pol-
ish. Double staining was performed, using the mouse
monoclonal antibody HT7 (1:1000; Pierce, MN1000),
which recognizes human tau (but not mouse tau) [50]
and the rabbit polyclonal antibody anti-porin (1:500;
Abcam, ab15895), a marker for mitochondria. The sec-
ondary antibodies goat anti-mouse IgG alexa488 (1:700;
Invitrogen, A11004) and goat anti-rabbit IgG alexa568
(Invitrogen, A11036) were used to detect HT7 and anti-
porin, respectively. In order to determine degenerating
neurons, we stained the sections with Fluoro-Jade B
according to manufacturer specifications (Millipore,
AG310). Next, we examined the brain sections using an
epifluorescence microscope (Nikon Eclipse 800)
equipped with a CoolSnap-FX monochrome CCD cam-
era (Photometrics, Tucson, AZ) using a standard Nikon
FITC and DAPI filters and acquired and analyzed the
images using the Metavue V7.1 software (Molecular
Devices, Downingtown, PA). To examine nuclear mor-
phology and degeneration, we performed hematoxylin
staining and acquired bright field images using a Nikon
Multizoom AZ100 microscope equipped with a Nikon
DS-2M color CCD camera (Nikon Instruments Inc,
Melville, NY).
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Intensity correlation analysis (ICA) is based on the prin-
ciple that for any set of values the sum of the differ-
ences from the mean equals zero, i.e., ΣN (Ai _ a)=0 ,
where a is the mean of the distribution with N values of
Ai. In our case, N is the number of pixels, and Ai is the
staining intensity for each pixel. It follows that for N
pixels associated with two sets of random staining inten-
sities (Ai and Bi), the sum of the product of their differ-
ences will also tend to zero; thus, ΣN(Ai _ a)(Bi _ b) ≈
0. However, this is not the case if the two intensities are
dependent (when the product tends to be a positive
value) or if they are segregated (when the product tends
to be a negative value). Thus, with dependent staining
ΣN (Ai - a )(Bi-b) > 0, whereas with segregated staining
ΣN(Ai-a)(Bi-b) < 0 [51]. We used this property to test
for dependent or segregated staining between HT7 and
anti-porin antibody. Analysis performed using Image-J
software (National Institutes of Health).
Statistical analysis
For protein quantification, the densitometry of each
band in the Western blot was normalized with tubulin.
All densitometry results represent the mean and stan-
dard deviations of all of the determinations performed.
Data were compared by one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
test. The criterion for statistical significance between
groups was P < 0.001. The same analysis was performed
for the quantification of Fluoro-Jade B positive cells. In
the case of the object recognition experiments, the dis-
crimination index data was analyzed using one-way
ANOVA, followed by a Tukey’sp o s t - h o ct e s t .T h ec r i -
terion for statistical significance was p < 0.01. We ana-
lyzed the percent of time spent with each object using
Student’s t-test. Specifically the time spent with the
novel object was compared with the time spent with the
familiar object in the same group. The criterion for sta-
tistical significance was p < 0.001. All statistical analyses
were performing using OriginPro 8.0 software.
Results
Tau oligomers impair memory encoding/consolidation
C57BL/6 male mice received stereotaxic subcortical
injections of either oligomeric, fibrillar, or monomeric
tau in the right hemisphere and PBS buffer in the left
hemisphere, a scheme summarized in Figure 1A, and
then we tested the animals in the novel-object recogni-
tion task. To compare our methods with the standard
heparin method, an additional control group was
injected with tau fibrils prepared according the standard
heparin protocol [30,31]. Figure 1B shows the precise
site of the injections, just above the CA1 region of the
hippocampus. We chose this site for the injection
according to previous studies that described large num-
ber of NFTs and extensive neuron loss from the CA1
region of the hippocampus in patients with AD in
comparison with age-matched controls [32-35]. Tau
oligomers and fibrils were characterized by AFM
(Figure 1D, E and 1F), and the oligomers were purified
by FPLC (Figure 1C) before injection. The oligomeric
species molecular weight indicates that it represents a
tau dimer/trimer, as previously described [36]. We
injected the tau preparations and PBS into the C57BL/6
mice 24 h before training in an arena containing two
objects that they could explore freely (familiarization
phase). Six hours later, we exposed the mice to one
familiar and one new object (test phase). Mice injected
with tau oligomers were unable to distinguish the new
object, with no significant difference in the percentage
of time spent investigating both objects (Figure 2A), and
displayed a discrimination index significantly lower than
that of the other three groups (Figure 2B). Neither
monomeric nor any of the fibrillar tau animals showed
memory deficits in this task (Figure 2A and 2B). These
data indicate that tau oligomers acutely disrupt antero-
grade memory storage, which parallels the anterograde
memory deficits in early-stage AD patients who are
unable to store newly-acquired information [37].
Tau oligomers induced neuronal degeneration
Next, we investigated the effects of different forms of
tau in neuronal degeneration. We harvested the brains
from six animals that underwent behavioral testing and
then fixed them in 4% buffered paraformaldehyde, and
embedded in paraffin. Cell damage was detected only in
the group injected with tau oligomers and only in the
CA1 region of the hippocampus in the right hemisphere
(Figure 3A, E and 3I.
To determine cell damage, we performed nuclear
staining using Hematoxylin (Figure 3A-D) and neuronal
staining was performed using NeuN antibody (Figure
3E-H). In both cases, tau oligomers were highly toxic,
producing great destruction of the pyramidal layer of
neurons in the hippocampal region, underneath the
injection site (Figure 3A and 3E). Tau fibrils also show
some degree of toxicity, but much less than tau oligo-
mers (Figure 3B and 3F). We detected cell damage
solely in the group injected with tau oligomers and only
i nt h eC A 1r e g i o no ft h eh i p p o c a m p u si nt h er i g h t
hemisphere (Figure 3). None of the mice displayed any
damage in the hippocampus of the left hemisphere
(Figure 3D, H, and 3L), demonstrating that the toxicity
produced by tau oligomers is located in the area of
injection, even at least 30 hours post-injection. The oli-
gomers that diffused to other areas of the hippocampus
did not produce neuronal damage (Additional File 1,
Figure 1), probably because of the low concentration of
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tion, we stained sections with Fluoro-Jade B, which is a
fluorescein derivative that specifically labels dying neu-
rons in the brain [38,39]. As seen in Figure 3, neurons
exposed to tau oligomers exhibit intense Fluoro-Jade B
labeling, which indicates a high level of neurodegenera-
tion. It was also possible to see some labeling in the
neurons treated with fibrils (Figure 3), but it is very low
in comparison with the group treated with oligomeric
tau. Fluoro-Jade B positive cells were counted and nearly
Figure 1 Experimental design and characterization of tau samples. (A) Mice were divided into four groups, one injected with tau oligomers
and PBS, a second group injected with tau fibrils and PBS a third group injected with tau monomers and PBS, and a fourth group injected with
tau heparin fibrils and PBS used as a control (*). (B) Schematic representation of a coronal section of a mouse brain with * indicating the
injection sites of the tau preparations in PBS. (C) FPLC profile of tau oligomers injected into mice brains. (D) AFM image showing homogeneous
population of tau oligomers (scale bar = 140 nm). (E) AFM image of tau fibrils (scale bar = 70 nm). (F) AFM images of tau fibrils prepared with
heparin (scale bar = 50 nm).
Figure 2 Tau oligomers impaired the recognition memory in mice. (A) Effects of tau oligomers, fibrils, and monomers on memory were
investigated in C57BL/6 mice by using the object recognition task. Histograms indicate the percentage of exploration of the familiar and novel
objects. Mice injected with monomers or fibrils spent significantly more time investigating the novel object versus mice injected with tau
oligomers, indicating impaired memory, as shown by their inability to recognize the familiar object. #p < 0.01 vs. novel object. (B) Histograms
show the corresponding discrimination index (mean ± SD) for the data shown in A. *p < 0.01. As a control, behavioral analyses were performed
on mice without injection.
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damage in the group injected with tau oligomers, com-
p a r e dt ol e s st h a n7 %i nt h eg r o u pi n j e c t e dw i t ht a u
fibrils. Fluoro-Jade B binds to polyaminergic products of
cellular degeneration, such as spermidine, cadaverine,
and putrescine [38,39]. These data demonstrate that tau
oligomers produce neuronal damage of the CA1 region
of the hippocampus, which is also typical in patients
with AD [34,35]. Using these same parameters, we
found that tau fibrils present some neuronal damage in
vivo, but clearly lower damage than tau oligomers
(Figure 3). The fact that tau fibrils present some toxicity
may be because the fibrils were partially broken-down
into smaller, oligomeric aggregates. In addition, we must
take into consideration that the fibrils were directly pre-
pared from tau oligomers, so there remains a possibility
that the injected solution contained a small amount of
tau oligomers and/or prefibrillar oligomers that could
explain the detectable amount of toxicity. To elucidate
this point, as we mentioned in the previous section, we
injected into another group of mice tau fibrils (0.9 mg/
mL) prepared using the heparin protocol [30,31]. This is
aw e l l - d e s c r i b e dp r o c e d u r et op r o d u c eh i g h l yp u r et a u
fibrils. Mice did not present any memory impairment
(Figure 2) or Fluoro-Jade B positive staining (data not
shown); suggesting that the mild cellular damage
observed in the group injected with fibrils prepared
from oligomers was due to the presence of oligomers in
the preparation. Using the fibrils prepared with heparin
showed no toxicity even when we injected twice the
amount of tau fibrils by using the same volume at twice
the original concentration of each tau species (1.8 mg/mL).
As observed in the original experiments, only the mice
injected with tau oligomers exhibited memory impairment
(Additional File 1, Figure 2). These data suggest that the
amount of oligomers in the tau fibrils is minimal; therefore,
Figure 3 In vivo neurotoxicity of tau oligomers. A-D) Nuclear staining (Hematoxylin) of the hippocampal region CA1 from the hemispheres
of mice injected with tau preparations or PBS (Scale bar = 20 μm). E-H) Neuronal staining using the antibody NeuN show neuronal damage in
the area injected with tau oligomers (E) in comparison with the other hemispheres injected with fibrils (F) monomers (G) and PBS (H) (scale bar
=1 0μm). (I-L) Higher toxicity of tau oligomers versus fibrils, monomers and PBS. Neurodegenerative pyramidal cells in the CA1 hippocampal
region were stained with Fluoro-Jade B, emitting green fluorescence (scale bar = 10 μm). M) Number of Fluoro-Jade B positive cells/Total
number of cells in the CA1 region, 63% of cells showed signs of damage in the group injected with tau oligomers, compared to less than 6.5%
in the group injected with tau fibrils. Data are represented as the mean ± SE. *p < 0.01.
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memory deficits in the mice.
Loss of synaptic markers in mice injected with tau
oligomers
Early changes in AD brains include loss of synapses.
This precedes the anomalous aggregation of protein
(amyloid plaques, NFTs) and correlates with cognitive
dysfunction [40,41]. The role of tau in this context has
yet to be ascertained, but several studies using in vivo
models gave evidence of the relevance of tau in synaptic
loss and synaptic dysfunction [11]. In the P301S mutant
human tau transgenic mice, Yoshiyama et al. detected
loss of hippocampal synapses and impaired synaptic
function [15]. A relevant point of that study is that
synaptic dysfunction appears before the formation of
NFTs, which gives evidence implicating synaptic pathol-
ogy as an early neurotoxic consequence of pathogenic
human tau expression culminating in progressive neuro-
degeneration [15]. In a recent study, Polydoro et al.
showed through behavioral and electrophysiological
experiments for the first time that an accumulation and
aggregation of non-mutant tau isoforms might cause
cognitive and synaptic dysfunction [14].
To assess the effect of different tau species on
synapses using biochemical and histochemical analyses,
we measured the levels of several proteins related to
synaptic function. These proteins included the synaptic
vesicle-associated proteins, synaptophysin, synapsin-1,
and septin-11. Synaptophysin is a vesicle-bound presy-
naptic protein, synapsin-1 regulates the reserve pool of
synaptic vesicles [42], and septin-11 is involved in vesi-
cle trafficking and may play a role in synaptic connectiv-
ity. For biochemical analysis, Western blot assays were
performed using the PBS-soluble brain fraction (six
mice per group) and subsequently the relative amount
of protein was quantified by densitometry and normal-
ized with tubulin. We observed a clear decrease in
synaptophysin in the group injected with tau oligomers
in comparison with the other two groups (Figure 4B).
We then confirmed this result by performing immuno-
histochemistry, where we saw a decrease of synaptophy-
sin density in the CA1 region of the brain hemisphere
injected with oligomers (Figure 5). No changes in synap-
tophysin level occurred in the brains injected with fibrils
or monomers, or in any hemisphere injected with PBS.
Thus, pre-synapses seem to be affected by tau oligomers
in the CA1 region of the hippocampus. Similar to the
synaptophysin measurements, the levels of septin-11
were significantly lower in the hemisphere injected with
tau oligomers in comparison with the hemispheres
injected with fibrils or monomers (Figure 4D). This
result indicates that tau oligomers may affect trafficking
and microtubule stability. In the case of synapsin-1, we
observed no statistical differences in the levels of this
protein between the different groups (Figure 4B). This
result suggests that tau aggregates do not affect the
maintenance of the reserve pool of synaptic vesicle. It is
important to mention that in all measurements, with
the three different synaptic markers, we did not observe
any differences between any of the hemispheres injected
with PBS and the hemispheres injected with tau mono-
mers (Figure 4).
Evidence of mitochondrial dysfunction in mice treated
with tau oligomers
In AD, mitochondrial abnormalities occur early in the
pathogenic process and likely play a significant role in
disease progression. Several studies have demonstrated
markedly reduced levels of mitochondrial proteins and
activity [43-45] in the brains of AD patients. Recently,
using transgenic mice overexpressing the P301L mutant
human tau protein, David et al. demonstrated mitochon-
drial dysfunction by proteomic and functional analysis
[46]. Specifically, they demonstrated reduced NADH-
ubiquinone oxidoreductase (complex I) activity and
impairment of mitochondrial respiration, and ATP
synthesis (complex V) with age in P301L mice. Quinta-
nilla et al. demonstrated that inducible expression of tau
truncated at Asp-421, to mimic caspase cleavage,
induced mitochondrial fragmentation and loss of mito-
chondrial membrane integrity [47]. In this study, we
examined the relationship between possible pathological
forms of tau and mitochondrial dysfunction.
Studies that correlate the stage of aggregation of tau
with mitochondrial abnormalities are in short supply. For
this reason, we measured the levels of mitochondrial com-
plexes I and V in all groups. We saw decreased levels of
NADH-ubiquinone oxidoreductase (electron transport
chain complex I) in the hemispheres injected with tau oli-
gomers in comparison with the ones injected with fibrils
or monomers (Figure 6B). This result correlates with pre-
vious studies of AD brains, suggesting that modifications
of mitochondrial encoded complex I subunit mRNA
[48,49], reduction in protein levels of the 24- and 75-kDa
subunits of complex I [45], and other mitochondrial dys-
function effects [46] can arise owing to tau accumulation
in the absence of massive formation of NFTs. In the case
of complex V levels, we did not observe any statistical dif-
ference between any of the groups (Figure 6C), demon-
strating that tau oligomers do not acutely affect the initial
state of ATP synthesis. Our results suggest that tau oligo-
mers initially affect complex I activity and complex V
could also be affected in a later state directly or indirectly
by the action of tau oligomers.
The fate of injected tau oligomers was investigated
(Figure 6E-H), double staining using the mouse monoclo-
nal antibody HT7 (Figure 6E), which recognizes human
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Page 7 of 14tau but not murine tau [50], and anti-porin antibody, as a
marker for mitochondria (Figure 6F); co-localization
between tau oligomers and mitochondria in CA1 cells
(Figure 6G);. This was confirmed by ICA of the signal
(Figure 6H), as described in [51], suggesting a direct
interaction between tau oligomers and mitochondria.
Neuronal commitment to apoptosis may occur
through a mitochondrial pathway employing caspase-9
or through an alternative, receptor-mediated pathway
involving caspase-8 [52]. Considering the role of mito-
chondrial dysfunction in AD, we examined the possible
activation of caspase-9 by using an antibody that
recognizes the active fragment of caspase-9. Western
blot analysis demonstrated a considerable activation of
caspase-9 in the hemispheres injected with tau oligo-
mers (Figure 6D). By using immunohistochemistry tech-
niques, we confirmed that the activation of caspase-9 is
mainly in the hemispheres injected with tau oligomers
and in varying levels in the hemispheres injected with
fibrils, which was not statistically significant according
to the biochemical analysis. We did not observe cas-
pase-9 activation in the hemispheres injected with the
monomer or PBS (Figure 7). These results are supported
by a recent study demonstrating a closer association
Figure 4 Tau oligomers induce synaptic dysfunction. (A) Representative Western blot of mouse hippocampus homogenate. The levels of
synaptophysin, synapsin-1, and septin-11 were measured by band quantification and normalized with the levels of tubulin. PBSo indicates
representative bands of hippocampal area injected with PBS in mice also injected with tau oligomers, PBSf indicates PBS injection in mice also
injected with tau fibrils, and PBSm indicates PBS injection in mice also injected with tau monomers. (B) Synaptophysin levels were significantly
lower in the hemispheres injected with tau oligomers in comparison with the ones injected with fibrils, monomers, or PBS. (C) No significant
differences in the levels of synapsin-1 were observed. (D) Only the hemisphere injected with tau oligomers presents a decrease in the level of
septin-11. Data are represented as the mean ± SE. *p < 0.01, n = 6
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Page 8 of 14between the formation of NFTs than Ab deposits in the
activation of caspase-9. Moreover, the same study con-
cludes that the activation of caspase-9 precedes tangle
formation [53]. We also did not detect caspase-8 activa-
tion in our study (data not shown).
Discussion
The role of soluble oligomeric forms of disease-asso-
ciated protein has received considerable attention in sev-
eral neurodegenerative diseases because of their
association with toxicity [54-56]. There is a growing
belief that intermediates in the formation of NFTs
encompass the pathogenic forms of tau [11,16,20,57-59].
Herein, we demonstrated that tau oligomers injected in
proximity of the hippocampus were responsible for
immediate memory impairment in mice by acutely dis-
rupting anterograde memory storage. These observa-
tions correlate with previous studies in humans and
primates that have shown hippocampal lesions to result
in impaired object recognition [60,61]. The neuronal
damage produced by tau oligomers in the CA1 region is
consistent with previous work, which shows that neuro-
degeneration in CA1 region occurs prior to the forma-
tion of NFTs and the clinical diagnosis of dementia in
AD patients [62]. This suggests that tau oligomers could
be responsible for neuronal death in the CA1 region in
AD or other tauopathies. In the specific case of AD,
NFTs progressively spread throughout the brain in an
anatomically stereotypical manner [63,64]. Based on
these and several other studies, it has been postulated
that tau proteins spread in a prion-like mechanism in
the tauopathies [65-67]. Clavaguera et al.’s observations
support this concept by demonstrating that intracerebral
injections of brain extract from mice with a filamentous
tau pathology (P301S mutation) induces the formation
and spreading of tau aggregates. The pathology spread
Figure 5 Decrease in synaptophysin in mice injected with tau oligomers. Brain sections were stained with antibody to the presynaptic
marker synaptophysin (green) nuclear staining with DAPI (blue). All images were taken from the CA1 region. Hemispheres injected with tau
oligomers exhibited a decreased in synaptophysin (A). No decrease in the signal was observed in the hemispheres injected with fibrils (B),
monomers (C), and PBS (D). (Scale bars = 10 μm.)
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Page 9 of 14Figure 6 Tau oligomers induce mitochondrial alterations. (A) Representative western blot of mouse brain homogenate. The levels of
complex I, complex V, and caspase-9 were measured by band quantification and normalized with the levels of tubulin. Abbreviations are as in
Fig. 4. (B) Complex I levels were significantly lower in the hemisphere injected with tau oligomers in comparison with the ones injected with
fibrils or monomers. (C) No differences in the levels of complex V were observed in any of the groups. (D) Caspase-9 activation was significantly
higher in tau oligomer groups over both tau fibril- and monomer-injected groups. (E-G) Double staining between human tau-specific antibody
HT7 (green fluorescence) and mitochondrial porin antibody (red fluorescence) demonstrates the internalization of tau oligomers in CA1 cells and
their interaction with the mitochondria. (H) The co-localization of tau oligomers with mitochondria was confirmed by ICA of the signal. Data are
represented as mean ± SE. *p < 0.01, n = 6.
Figure 7 Caspase-9 activation in hemisphere injected with tau oligomers. Immunofluorescence using an antibody for pro-caspase-9 was
performed. (A and B) Caspase-9 activation (green fluorescence) was observed in hemispheres injected with tau oligomers (A) or fibrils (B).
However, the levels of activation were significantly higher in the hemispheres injected with oligomers compared with fibrils, which is not
significant. (C and D). No activation of caspase-9 was observed in the hemispheres injected with tau monomers (C) or PBS (D). Nucleus was
stained with DAPI (blue). (Scale bars = 10 μm.).
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Page 10 of 14from the injection site to neighboring brain regions 15
months post-injection in transgenic mice for human
wild-type tau (ALZ17 mouse model) [66] and 12
months post-injection in wild-type mice.
The neurodegeneration produced by tau oligomers
occurred exclusively in the regions at the injection site
(CA1 region). In future studies it will be necessary to
establish several time points and work with transgenic
mouse models that express tau in order to determine if
tau oligomers induce endogenous tau aggregation and
spread into further areas of the brain. Nevertheless, our
results are in accordance with previous in vitro studies
that reveal extracellular tau to be toxic to neuronal cells,
and aggregated tau to be capable of propagation from
the outside to the inside of a cell [68-70]. On the basis
of their results, Gomez-Ramos et al. suggested that
NFTs, or other compounds released by degenerating
neurons, may accumulate in the extracellular space and
this could be toxic to the surrounding cells [68]. Frost
et al. showed that cultured cells take up extracellular
aggregated tau, but not monomers, and that the interna-
lized tau aggregates induce fibrillization of intracellular
tau. Moreover, they observed that newly aggregated
intracellular tau transfers between co-cultured cells [69].
If we take into consideration these studies and the novel
data presented in our study, we can postulate that tau
oligomers generated intracellularly could be released
either by binding and local rupture of the membrane, or
after cell death. The oligomers in the extracellular space
could be taken-up by healthy neurons in the vicinity dis-
rupt normal activity and stimulate further aggregation of
functional monomeric tau. Our results show that tau
oligomers are co-localized with mitochondria and dis-
play intraneuronal punctuate staining with HT7 anti-
body, indicative of the internalization of injected tau
oligomers.
Others in the field propose that a connection between
tau pathology and mitochondrial impairment is prevalent
[46,47]. Several studies suggest that in AD, mitochondrial
abnormalities occur early in the pathogenic process and
likely play a significant role in disease progression. In our
study, we observed that the injected oligomers co-loca-
lized with the mitochondrial marker porin, providing
further evidence of a pathological relation between oligo-
meric tau and mitochondrial dysfunction. Tau oligomers
may impair microtubule stability and trafficking, which
can affect the distribution of various organelles, including
mitochondria. Mitochondria travel for long distances to
fulfill the high-energy demand of synapses; thus, inhibi-
tion of transport disrupts the supply lines for energy. An
alternative approach of how tau can affect synapses could
be the direct inhibition of energy production through the
mitochondria in the synapses. We found decreased levels
of complex I in the hemispheres injected with tau
oligomers as compared with the brains injected with
fibrils or monomers. This decrease in complex I may lead
to severe energy impairments in synapses, as a reduction
in the activity of complex I of only 25% impairs energy
metabolism in synaptic mitochondria [71], whereas a
reduction of complex I activity by 72% is necessary to
impair energy metabolism in non-synaptic mitochondria
[72]. We did not observe statistical significances in com-
plex V levels between any of the groups. This relates well
with the data presented by David et al., where age affects
complex V, but decreases in complex I occur early in the
disease process [46], suggesting tau oligomers could
affect complex V in a later stage of pathology, either
directly or indirectly. Overall, according to our results,
we can postulate that tau oligomers inhibit energy pro-
duction through complex I, which can produce synaptic
alterations in synaptic-localized mitochondria.
In AD brains loss of synapses precedes NFTs forma-
tion and correlates with cognitive dysfunction [40,41].
Even though the role of tau in this context remains
unclear, in studies of other models of tauopathies and in
several tau mouse models [14,15], the authors reported
synaptic damage [73-75]. A recent study showed that
missorting of tau in neurons causes degeneration of
synapses, and the authors suggest that synaptic decay
could be caused by some oligomeric form of tau that is
not currently well defined [76]. Moreover, a very recent
s t u d yb yK i m u r ae ta l .d e m o n s trated that in wild-type
tau Tg mice, an early stage of tau aggregation (sarkosyl-
soluble) produced synaptic loss and memory impairment
[77]. To further investigate synaptic alternations, we
measured levels of characterized synaptic markers:
synaptophysin and septin-11, which are involved in
synaptic vesicle docking and trafficking, and synapsin-1,
which is associated with the vesicle reserve pool. We
found that only tau oligomers caused a decrease in
synaptophysin and septin-11; however, no difference
existed in the levels of synapsin-1 between all the
groups. These results suggest that tau oligomers can
affect presynaptic density and neuronal trafficking, but
do not interfere with the reserved pool of synaptic vesicles.
Another effect of mitochondrial dysfunction is the activa-
tion of the mitochondrial apoptotic pathway, measured by
activation of caspase-9. We measured an increase in cas-
pase-9 activation in the hemispheres injected with tau oli-
gomers, but not in the PBS-injected hemispheres. Earlier
studies demonstrated the presence of activated caspase-9
in synaptosomal preparation of AD brains [78]. A possible
explanation for the caspase activation could be that tau
oligomers accumulate at the mitochondrial membrane,
resulting in the release of cytochrome C, which leads to
caspase-9 activation through a complex with apoptotic
peptidase activating factor-1 (Apaf-1) [79]. This mechan-
ism has been suggested for other amyloidogenic proteins
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Page 11 of 14such as a-synuclein, Ab, and PrP [80,81]. Even more,
recently de Calignon et al, demonstrated that caspase acti-
vation precedes NFTs formation, suggesting that soluble
tau species, rather than fibrillar tau, may be the critical
toxic moiety underlying neurodegeneration [82].
The field of tau oligomers and other pre-filament tau
aggregates is becoming an extremely important area of
research in neurodegenerative diseases. Thus, under-
standing the negative impact of tau oligomers in neuro-
nal damage, specifically in reference to important
cellular mechanisms, such as mitochondrial and synaptic
function, will likely be of great importance to under-
stand the relevant disease processes and progression in
AD and other tauopathies. These results support the
hypothesis that tau oligomers are the acutely toxic spe-
cies in tau aggregation, and the disruption of mitochon-
drial membrane, the activation of the apoptotic-related
caspase-9, and reduction in complex I levels can cause
this toxicity, leading to the inhibition of synaptic energy
production due to tau oligomers. These cellular dysfunc-
tions may underlie the synaptic dysfunction and mem-
ory impairments observed with tau oligomers in this
study.
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